GSK and Novartis show appeal of asset swaps

1 May 2014 - Deborah Wilkes

Archived

When GlaxoSmithKline and Novartis unveiled their unusual three-part transaction on 22 April 2014, they demonstrated the appeal of asset swaps to pharmaceutical companies seeking to reshape their businesses. The global OTC industry will be transformed by the broad and complex deal encompassing oncology products and vaccines as well as consumer healthcare, and more asset swaps may be in the pipeline.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: